The investigational monoclonal antibody Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), top-line results of the Phase 3 TERRANOVA trial have shown. The disappointing results follow previously announced data from the Phase 3 GALATHEA trial that also showed the candidate…
Top-line results of a Phase 3 trial showed that treatment candidate Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), AstraZeneca and its subsidiary MedImmune announced. The multi-center, double-blind GALATHEA (NCT02138916) study is part of AstraZeneca’s VOYAGER…
AstraZeneca is presenting a broad selection of its novel respiratory disease medicines through more than 60 abstracts and scientific presentations at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. Presentations highlight combinations, respiratory biologics, and scientific research projects that target new pathways…
Get regular updates to your inbox.